DOCSLIB.ORG

Acute Jaundice Liver Function and the Results of Other Weight Gain, but in Severe Forms Oedema Standard Liver Tests Are Otherwise Normal and Ascites May Be Present

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acute Jaundice Liver Function and the Results of Other Weight Gain, but in Severe Forms Oedema Standard Liver Tests Are Otherwise Normal and Ascites May Be Present CME General Internal Medicine for the Physician – II Acute jaundice Liver function and the results of other weight gain, but in severe forms oedema standard liver tests are otherwise normal and ascites may be present. Bruising may in all three conditions. be spontaneous or at sites of venepunc- ture. Serum biochemistry shows increase Andrew Burroughs FRCP in transaminases, while serum albumin Lucy Dagher MD Liver disease levels may be low and prothrombin time Liver Transplantation & Hepatobiliary Generalised impairment of hepato- prolonged. Medicine, Royal Free Hospital, London cellular function may result from acute liver injury or chronic disease. A variety Obstruction of the bile ducts Clin Med JRCPL 2001;1:285–9 of disorders can produce acute or subacute hepatocellular injury The bile ducts may be obstructed including: because of mechanical obstruction of the The normal serum bilirubin concentra- viral hepatitis biliary tree by the presence of stones or tion in adults is less than 18 mmol/l. exposure to hepatotoxins by intrinsic disorders of the bile duct and Jaundice is best looked for in the sclerae extrinsic compression, most commonly hepatic ischaemia and mucous membrane of the soft palate cholangiocarcinoma and carcinoma of and is a common sign in almost all liver certain metabolic derangements. the pancreas, respectively. Without and biliary tract diseases. There are sev- Jaundice appears over days or weeks. mechanical obstruction the most eral important questions of value in Fatigue and malaise are common. There common causes of cholestatic jaundice determining the diagnosis which the may be varying degrees of decompensa- are drug induced and following hepatitis clinician should ask himself/herself: tion due to cirrhosis or just cutaneous A. The patient does not have signs of 1Is the jaundice due to an markers of chronic liver disease. Signs of chronic liver disease but may have signs obstruction of the biliary tree? hepatic encephalopathy, if present, may indicating malignancy. Pruritus is usual, 2Is there evidence of chronic liver be personality change, and in more and the patient becomes increasingly disease? severe cases manifest as flapping tremor, pigmented. There are raised levels of confusion and coma. Fluid retention in conjugated bilirubin, biliary alkaline 3Is the jaundice possibly drug its mildest form may be exhibited as phosphatase and total cholesterol in the induced, alcohol induced or infective in origin? 4Is there any evidence of haemolysis? Fig 1. Classification of jaundice. Classification of jaundice (Fig 1) JAUNDICE Jaundice can result from either an increase in bilirubin formation or a decrease in hepatic clearance. From a Hepatocellular practical standpoint, it is reasonable to Isolated bilirubin Cholestatic classify conditions that produce jaundice transport defects haemolysis under three broader categories: Acute Chronic 1Isolated disorders of bilirubin Dilated ducts Undilated ducts metabolism. 2Liver disease. 3Obstruction of the bile ducts. Table 1. Disorders of bilirubin metabolism. Unconjugated hyperbilirubinaemia: Isolated disorders of bilirubin Increased bilirubin production Haemolysis metabolism (Table 1) Ineffective erythropoiesis The mechanisms that can lead toisolated Blood transfusion Resorption of haematomas unconjugated hyperbilirubinaemia are: Decreased hepatocellular uptake Drugs (eg rifampicin) increased bilirubin production Gilbert syndrome decreased hepatocellular uptake Decreased conjugation Gilbert syndrome decreased bilirubin conjugation. Crigler-Najar syndrome Physiologic jaundice of the newborn Hyperbilirubinaemia is often associ- Conjugated or mixed hyperbilirubinaemiaD ubin-Johnson syndrome ated with a predominant elevation in Rotor syndrome indirect serum bilirubin concentration. Clinical Medicine Vol 1No 4 July/August 2001 285 CME General Internal Medicine for the Physician – II Key Points some can cause haemolysis. Drug inges- tion may need to be sought by searching Scleral jaundice can be detected if serum bilirubin is above 34 mmol/l, but more the patient’s home and workplace and by commonly 50 mmol/l is the threshold re-taking the history as well as checking general practitioner (GP) records. A careful history, physical examination and review of the standard laboratory tests Ingestion of significant quantities of should allow a physician to make an accurate diagnosis in 85% of cases paracetamol or the mushroom Amanita In acute jaundice, liver ultrasound should be the first imaging modality phalloides may lead to hepatocellular necrosis and jaundice within several days If there is evidence of biliary obstruction and a therapeutic intervention is planned, of exposure 2. Toxic liver injury can have a endoscopic retrograde cholangiopancreatography or percutaneous transhepatic cholangiography is the investigation of choice fulminant course associated with a high mortality. Several drugs can produce Magnetic resonance cholangiopancreatography should follow ultrasound if the idiosyncratic hepatocellular injury and latter has been technically difficult, if obstruction has not been ruled out or jaundice, the most common being non- therapeutic intervention is not needed steroidal anti-inflammatory drugs Liver biopsy is needed to confirm the presence, cause and severity of chronic liver (NSAIDs), amiodarone, terbinafine, iso- disease niazid, methyldopa, phenytoin and the inhalational anaesthetic halothane. Excessive alcohol intake is especially serum. Steatorrhoea is responsible for increased exposure not only to viral important because it is common; a weight loss and malabsorption of cal- hepatitis but also to a greater number of detailed history of alcohol consumption cium and fat-soluble vitamins A, D, E rarer causes of jaundice such as malaria, should be taken from the patient, rela- and K. and inherited haemoglobinopathies. A tives and the GP. Alcoholic hepatitis In adult patients with new onset of family history is important with regard should be a diagnostic consideration in jaundice, eight disorders account for to heritable disorders of bilirubin metab- the jaundiced patient with ethanol 98% of the diagnoses ultimately olism such as Gilbert syndrome, chronic dependency, particularly when hepato- established 1: liver disease such as Wilson’s disease, megaly and fever are present. viral hepatitis haemochromatosis and autoimmune Physical examination alcoholic liver disease conditions which may be associated with chronic active hepatitis or PBC. Special chronic hepatitis Signs and symptoms attention should be paid to identifying drug induced liver diseases groups at particular risk of contracting A history of fever, especially accom- gallstones and their complications infective viral hepatitis such as intra- panied by shaking chills, or abdominal carcinoma of the pancreas venous (IV) drug abusers, homosexuals, pain particularly in the right upper primary biliary cirrhosis (PBC) following needle-stick injuries or contact quadrant, is suggestive of cholangitis primary sclerosing cholangitis. with jaundiced individuals, and patients caused by obstructive diseases (particu- who have received blood transfusions. larly choledocholithiasis), as is a history By the time patients with metastatic Drugs and environmental hepato- of biliary surgery. Symptoms compatible liver disease develop jaundice, the diag- toxins may not only be hepatotoxic but with viral prodrome, such as anorexia, nosis is usually obvious because the liver has been extensively replaced by tumour tissue. Fig 2. History taking in acute jaundice. Careful history, physical examination Raw fish and review of standard laboratory tests Transfusion and Newborns of should allow a physician to make an transplant recipients long-term carriers accurate diagnosis in 85% of cases 1. Alcohol Multiple Family history sexual partners History History (Fig 2) Intravenous Prescription taking drug users An accurate clinical history is medication in acute Over-the-counter jaundice particularly important in differentiating drugs Prisoners the various causes of jaundice. In con- Vitamins Institutionalised junction with examination, it determines Herbal remedies people the most appropriate investigations. Healthcare Body-piercing, The increase in foreign travel and workers Hepatoxins tattoos migration to developed countries have 286 Clinical Medicine Vol 1No 4 July/August 2001 CME General Internal Medicine for the Physician – II Table 2. Signs and symptoms of viral hepatitis. aspartate aminotransferase to alanine aminotransferase appears to be a useful Infection index for distinguishing non-alcoholic Short-term Long-term steatohepatitis (NASH) from alcoholic (acute) (chronic) liver disease. Although ratios less than 1 suggest NASH or viral hepatitis, a ratio Tiredness, anorexia, malaise, myalgias Same symptoms as acute of 2 or above strongly suggests alcoholic Nausea or stomach ache Muscle and joint ache liver disease 3,4. Gamma-glutamyl trans- Diarrhoea Weakness Skin rash Signs & symptoms of cirrhosis ferase elevation strengthens the diagnosis Yellow eyes/skin (jaundice) Signs & symptoms of liver cancer of alcohol abuse. A drug effect is possible Light-coloured stools Secondary amenorrhoea if there is a correlation between the onset Dark yellow urine of jaundice, elevation of liver enzymes and the start of drug administration. The drugs that most commonly cause malaise and myalgias point to viral which the liver is usually enlarged. The transaminase abnormalities are NSAIDs, hepatitis (Table 2). Systemic features
Load more

Recommended publications
  • Skin Manifestations of Liver Diseases
    medigraphic Artemisaen línea AnnalsA Koulaouzidis of Hepatology et al. 2007; Skin manifestations6(3): July-September: of liver 181-184diseases 181 Editorial Annals of Hepatology Skin manifestations of liver diseases A. Koulaouzidis;1 S. Bhat;2 J. Moschos3 Introduction velop both xanthelasmas and cutaneous xanthomas (5%) (Figure 7).1 Other disease-associated skin manifestations, Both acute and chronic liver disease can manifest on but not as frequent, include the sicca syndrome and viti- the skin. The appearances can range from the very subtle, ligo.2 Melanosis and xerodermia have been reported. such as early finger clubbing, to the more obvious such PBC may also rarely present with a cutaneous vasculitis as jaundice. Identifying these changes early on can lead (Figures 8 and 9).3-5 to prompt diagnosis and management of the underlying condition. In this pictorial review we will describe the Alcohol related liver disease skin manifestations of specific liver conditions illustrat- ed with appropriate figures. Dupuytren’s contracture was described initially by the French surgeon Guillaume Dupuytren in the 1830s. General skin findings in liver disease Although it has other causes, it is considered a strong clinical pointer of alcohol misuse and its related liver Chronic liver disease of any origin can cause typical damage (Figure 10).6 Therapy options other than sur- skin findings. Jaundice, spider nevi, leuconychia and fin- gery include simvastatin, radiation, N-acetyl-L-cys- ger clubbing are well known features (Figures 1 a, b and teine.7,8 Facial lipodystrophy is commonly seen as alco- 2). Palmar erythema, “paper-money” skin (Figure 3), ro- hol replaces most of the caloric intake in advanced al- sacea and rhinophyma are common but often overlooked coholism (Figure 11).
    [Show full text]
  • 6.14 Alcohol Use Disorders and Alcoholic Liver Disease
    6. Priority diseases and reasons for inclusion 6.14 Alcohol use disorders and alcoholic liver disease See Background Paper 6.14 (BP6_14Alcohol.pdf) Background The WHO estimates that alcohol is now the third highest risk factor for premature mortality, disability and loss of health worldwide.1 Between 2004 to 2006, alcohol use accounted for about 3.8% of all deaths (2.5 million) and about 4.5% (69.4 million) of Disability Adjusted Life Years (DALYS).2 Europe is the largest consumer of alcohol in the world and alcohol consumption in this region emerges as the third leading risk factor for disease and mortality.3 In European countries in 2004, an estimated one in seven male deaths (95 000) and one in 13 female deaths (over 25 000) in the 15 to 64 age group were due to alcohol-related causes.3 Alcohol is a causal factor in 60 types of diseases and injuries and a contributing factor in 200 others, and accounts for 20% to 50% of the prevalence of cirrhosis of the liver. Alcohol Use Disorders (AUD) account for a major part of neuropsychiatric disorders and contribute substantially to the global burden of disease. Alcohol dependence accounts for 71% of all alcohol-related deaths and for about 60% of social costs attributable to alcohol.4 The acute effects of alcohol consumption on the risk of both unintentional and intentional injuries also have a sizeable impact on the global burden of disease.2 Alcoholic liver disease (ALD) is the commonest cause of cirrhosis in the western world, and is currently one of the ten most common causes of death.5 Liver fibrosis caused by alcohol abuse and its end stage, cirrhosis, present enormous problems for health care worldwide.
    [Show full text]
  • Diagnosis and Management of Primary Biliary Cholangitis Ticle
    REVIEW ArtICLE 1 see related editorial on page x Diagnosis and Management of Primary Biliary Cholangitis TICLE R Zobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD1, David Bernstein, MD, FAASLD, FACG, AGAF, FACP2, Mitchell L. Shifman, MD3, Paul Kwo, MD4, W. Ray Kim, MD5, Kris V. Kowdley, MD6 and Ira M. Jacobson, MD7 Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune disease with a variable progressive course. PBC can cause debilitating symptoms including fatigue and pruritus and, if left untreated, is associated with a high risk of cirrhosis and related complications, liver failure, and death. Recent changes to the PBC landscape include a REVIEW A name change, updated guidelines for diagnosis and treatment as well as new treatment options that have recently become available. Practicing clinicians face many unanswered questions when managing PBC. To assist these healthcare providers in managing patients with PBC, the American College of Gastroenterology (ACG) Institute for Clinical Research & Education, in collaboration with the Chronic Liver Disease Foundation (CLDF), organized a panel of experts to evaluate and summarize the most current and relevant peer-reviewed literature regarding PBC. This, combined with the extensive experience and clinical expertise of this expert panel, led to the formation of this clinical guidance on the diagnosis and management of PBC. Am J Gastroenterol https://doi.org/10.1038/s41395-018-0390-3 INTRODUCTION addition, diagnosis and treatment guidelines are changing and a Primary biliary cholangitis (PBC) is a chronic, cholestatic, auto- number of guidelines have been updated [4, 5]. immune disease with a progressive course that may extend over Because of important changes in the PBC landscape, and a num- many decades.
    [Show full text]
  • Alcoholic Liver Disease and Its Relationship with Metabolic Syndrome
    Research and Reviews Alcoholic Liver Disease and Its Relationship with Metabolic Syndrome JMAJ 53(4): 236–242, 2010 Hiromasa ISHII,*1 Yoshinori HORIE,*2 Yoshiyuki YAMAGISHI,*3 Hirotoshi EBINUMA*3 Abstract Alcoholic liver disease (ALD), which occurs from chronic excessive drinking, progresses from initial alcoholic fatty liver to more advanced type such as alcoholic hepatitis, liver fibrosis, or liver cirrhosis when habitual drinking continues. In general, chance of liver cirrhosis increases after 20 years of chronic heavy drinking, but liver cirrhosis can occur in women after a shorter period of habitual drinking at a lower amount of alcohol. Alcoholic liver cirrhosis accounts for approximately 20% of all liver cirrhosis cases. The key treatment is abstinence or substantial cutting down on drinking; the prognosis is poor if the patient continues drinking after being diagnosed with liver cirrhosis. Factors that exert adverse effects on the progression of ALD include gender difference, presence of hepatitis virus, immunologic abnormality, genetic polymorphism of alcohol-metabolizing enzymes, and complication of obesity or overweight. Recently, particular attention has been paid to obesity and overweight as risk factors in the progression of ALD. Conditions such as visceral fat accumulation, obesity, and diabetes mellitus underlie the pathologic factor of metabolic syndrome (MetS). In liver, MetS may accompany fatty liver or steatohepatitis, with possible progression to liver cirrhosis in some cases. Caution is required for patients with MetS who have a high alcohol intake because alcohol consumption further accelerates the progression of liver lesions. Key words Alcoholic liver disease, Metabolic syndrome, Obesity, NAFLD/NASH Introduction following hypertension and smoking, as a global disease burden.
    [Show full text]
  • Vaccinations for Adults with Chronic Liver Disease Or Infection
    Vaccinations for Adults with Chronic Liver Disease or Infection This table shows which vaccinations you should have to protect your health if you have chronic hepatitis B or C infection or chronic liver disease (e.g., cirrhosis). Make sure you and your healthcare provider keep your vaccinations up to date. Vaccine Do you need it? Hepatitis A Yes! Your chronic liver disease or infection puts you at risk for serious complications if you get infected with the (HepA) hepatitis A virus. If you’ve never been vaccinated against hepatitis A, you need 2 doses of this vaccine, usually spaced 6–18 months apart. Hepatitis B Yes! If you already have chronic hepatitis B infection, you won’t need hepatitis B vaccine. However, if you have (HepB) hepatitis C or other causes of chronic liver disease, you do need hepatitis B vaccine. The vaccine is given in 2 or 3 doses, depending on the brand. Ask your healthcare provider if you need screening blood tests for hepatitis B. Hib (Haemophilus Maybe. Some adults with certain high-risk conditions, for example, lack of a functioning spleen, need vaccination influenzae type b) with Hib. Talk to your healthcare provider to find out if you need this vaccine. Human Yes! You should get this vaccine if you are age 26 years or younger. Adults age 27 through 45 may also be vacci- papillomavirus nated against HPV after a discussion with their healthcare provider. The vaccine is usually given in 3 doses over a (HPV) 6-month period. Influenza Yes! You need a dose every fall (or winter) for your protection and for the protection of others around you.
    [Show full text]
  • The Role of the Microbiome in Liver Cancer
    cancers Review The Role of the Microbiome in Liver Cancer Mar Moreno-Gonzalez 1 and Naiara Beraza 1,2,* 1 Gut Microbes and Health Institute Strategic Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UQ, UK; [email protected] 2 Food Innovation and Health Institute Strategic Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UQ, UK * Correspondence: [email protected] Simple Summary: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth most common cause of cancer-related deaths worldwide; its incidence and mortality rate continue to increase. HCC has a poor prognosis and the curative options are very limited. The liver is closely connected (anatomically and functionally) to the gastrointestinal tract, which represents the largest reservoir of microbes in our body. Increasing evidence implicates communication between the liver and the intestine (and its microbiome) in the progression of chronic liver disease to liver cancer. In this review, we summarise current knowledge on the role of the gut–liver axis in contributing to the progression of HCC, with a focus on the impact of the intestinal microbiome in this process. We also review the potential of therapeutic strategies based on modulation of the microbiome for the prevention of HCC progression. Abstract: Hepatocellular carcinoma (HCC) is the most common malignancy occuring in the context of chronic liver disease and is one of the main causes of cancer-derived death worldwide. The lack of effective treatments, together with the poor prognosis, underlines the urge to develop novel and multidisciplinary therapeutics. An increasing body of evidence shows that HCC associates with changes in intestinal microbiota abundance and composition as well as with impaired barrier function, Citation: Moreno-Gonzalez, M.; leading to the release of bacteria and their metabolites to the liver.
    [Show full text]
  • Diagnosis and Management of Primary Sclerosing Cholangitis
    AASLD PRACTICE GUIDELINES Diagnosis and Management of Primary Sclerosing Cholangitis Roger Chapman,1 Johan Fevery,2 Anthony Kalloo,3 David M. Nagorney,4 Kirsten Muri Boberg,5 Benjamin Shneider,6 and Gregory J. Gores7 Preamble classification used by the Grading of Recommendation This guideline has been approved by the American Asso- Assessment, Development, and Evaluation (GRADE) ciation for the Study of Liver Diseases and represents the workgroup with minor modifications (Table 1).3 The position of the Association. These recommendations pro- strength of recommendations in the GRADE system are vide a data-supported approach. They are based on the classified as strong (class 1) or weak (class 2). The quality following: (1) formal review and analysis of the recently- of evidence supporting strong or weak recommendations published world literature on the topic (Medline search); is designated by one of three levels: high (level A), mod- (2) American College of Physicians Manual for Assessing erate (level B), or low-quality (level C). Health Practices and Designing Practice Guidelines1; (3) guideline policies, including the AASLD Policy on the Definition and Diagnosis Development and Use of Practice Guidelines and the Definitions. Primary sclerosing cholangitis (PSC) is a American Gastroenterological Association Policy State- chronic, cholestatic liver disease characterized by inflam- ment on Guidelines2; and (4) the experience of the au- mation and fibrosis of both intrahepatic and extrahepatic thors in the specified topic. bile ducts,4 leading to the formation of multifocal bile Intended for use by physicians, these recommenda- duct strictures. PSC is likely an immune mediated, pro- tions suggest preferred approaches to the diagnostic, ther- gressive disorder that eventually develops into cirrhosis, apeutic and preventative aspects of care.
    [Show full text]
  • Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders
    Journal of Clinical Medicine Review Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders Cristiana Bianco 1 , Elena Coluccio 1, Daniele Prati 1 and Luca Valenti 1,2,* 1 Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] (C.B.); [email protected] (E.C.); [email protected] (D.P.) 2 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy * Correspondence: [email protected]; Tel.: +39-02-50320278; Fax: +39-02-50320296 Abstract: Anemia is a common feature of liver and bowel diseases. Although the main causes of anemia in these conditions are represented by gastrointestinal bleeding and iron deficiency, autoimmune hemolytic anemia should be considered in the differential diagnosis. Due to the epidemiological association, autoimmune hemolytic anemia should particularly be suspected in patients affected by inflammatory and autoimmune diseases, such as autoimmune or acute viral hepatitis, primary biliary cholangitis, and inflammatory bowel disease. In the presence of biochemical indices of hemolysis, the direct antiglobulin test can detect the presence of warm or cold reacting antibodies, allowing for a prompt treatment. Drug-induced, immune-mediated hemolytic anemia should be ruled out. On the other hand, the choice of treatment should consider possible adverse events related to the underlying conditions. Given the adverse impact of anemia on clinical outcomes, maintaining a high clinical suspicion to reach a prompt diagnosis is the key to establishing an adequate treatment. Keywords: autoimmune hemolytic anemia; chronic liver disease; inflammatory bowel disease; Citation: Bianco, C.; Coluccio, E.; autoimmune disease; autoimmune hepatitis; primary biliary cholangitis; treatment; diagnosis Prati, D.; Valenti, L.
    [Show full text]
  • Hepatitis C and Alcohol
    Hepatitis C and Alcohol Eugene R. Schiff, M.D., and Nuri Ozden, M.D. Patients infected with the hepatitis C virus (HCV) who drink heavily are likely to suffer more severe liver injury, promoting disease progression to cirrhosis and increasing their risk for liver cancer. Some research, although not conclusive, suggests that even moderate drinking may spur liver damage in HCV-infected patients. Research areas that have the greatest potential for developing more effective treatment options include HCV virology, immunology, animal models, and the mechanisms of liver injury. KEY WORDS: hepatitis C virus; alcoholic beverage; chronic AODE (alcohol and other drug effects); amount of AOD use; epidemiology; risk factors; disease course; alcoholic liver cirrhosis; gender differences; biochemical mechanism; RNA; mutation; apoptosis; inflammation; hepatocellular carcinoma; regulatory proteins; immune response; alcoholic fatty liver; treatment issues; treatment outcome; interferon epatitis C is an infectious liver the time of infection, male gender, are considerably more likely to test disease caused by the hepatitis obesity, abnormal accumulation of fat positive for HCV infection than those HC virus (HCV). The virus, in the liver (a condition known as fatty with less severe liver disease (Takase et which causes inflammation in the liver liver, or steatosis), and excessive alco­ al. 1993). and can lead to more serious illness, hol consumption (Poynard et al. 2001). primarily is spread by intravenous This article discusses the mechanisms contact with the blood of an infected by which alcohol may exacerbate Levels of Alcohol person. About 4 million people in the HCV-infected patients’ risk of disease Consumption in HCV United States have been infected, progression, reviews issues in the Patients and the Risk of making it the Nation’s most common treatment of alcoholic patients with Further Liver Disease blood-borne disease, resulting in the HCV infection, and addresses impor­ deaths of between 10,000 and 12,000 tant areas of future research.
    [Show full text]
  • Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases 1 2 3 4 5 Keith D
    | PRACTICE GUIDANCE HEPATOLOGY, VOL. 0, NO. 0, 2018 Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases 1 2 3 4 5 Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, and Marlyn Mayo Intended for use by health care providers, this guid- Preamble ance identifies preferred approaches to the diagnostic This American Association for the Study of and therapeutic aspects of care for patients with PBC. Liver Diseases (AASLD) 2018 Practice Guidance As with clinical practice guidelines, it provides gen- on Primary Biliary Cholangitis (PBC) is an update eral guidance to optimize the care of the majority of of the PBC guidelines published in 2009. The 2018 patients and should not replace clinical judgment for updated guidance on PBC includes updates on etiol- a unique patient. ogy and diagnosis, role of imaging, clinical manifesta- The major changes from the last guideline to this tions, and treatment of PBC since 2009. The AASLD guidance include information about obeticholic acid 2018 PBC Guidance provides a data-supported (OCA) and the adaptation of the guidance format. approach to screening, diagnosis, and clinical man- agement of patients with PBC. It differs from more recent AASLD practice guidelines, which are sup- Etiology of Primary Biliary ported by systematic reviews and a multidisciplinary panel of experts that rates the quality (level) of the Cholangitis evidence and the strength of each recommendation Primary Biliary Cholangitis (PBC) is considered using the Grading of Recommendations Assessment, an autoimmune disease because of its hallmark sero- Development, and Evaluation system. In contrast, this logic signature, antimitochondrial antibody (AMA), (1-4) guidance was developed by consensus of an expert and specific bile duct pathology.
    [Show full text]
  • Primary Biliary Cholangitis
    LIVER DISORDERS, SERIES #4 Rad Agrawal, MD, FACP, FACG, AGAF, FASGE Primary Biliary Cholangitis Duminda Suraweera Courtney Reynolds Shehan Thangaratnam Gaurav Singhvi Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a chronic, cholestatic, inflammatory liver disease characterized by destruction of intrahepatic bile ducts resulting in progressive liver damage. The etiology of primary biliary cholangitis is still not fully understood but likely involves both environmental and genetic factors. If symptomatic, patients often present with fatigue and pruritus. About 95% of individuals with primary biliary cholangitis will have a positive anti- mitochondrial antibody. Current treatment options are limited primarily to ursodeoxycholic acid, while those with decompensated liver disease will require liver transplantation. We provide a review of the etiology, pathogenesis, natural history, diagnosis and management of primary biliary cholangitis. EPIDEMIOLOGY, ETIOLOGY AND PATHOGENESIS rimary biliary cholangitis (PBC) has an incidence The etiology of PBC is not fully understood, but rate of 0.9 to 5.8 per 100,000 people with an both genetic predisposition and environmental triggers Pestimated female to male ratio of 10 to 1.1-3 PBC likely play an important role. The prevalence of PBC is is more common in patients in Northern Europe, the higher in families with an affected member, indicating United Kingdom and the northern United States. The a possible genetic component. Approximately 1.2% of prevalence seems to have increased over time, currently children of PBC patients develop PBC, with the highest ranging from 1.91 to 40.2 per 100,000 people.3 The risk in daughters of women with PBC.4 Monozygotic increase in prevalence is likely multifactorial with twins have a high concordance rate of 0.63 for PBC.5 increased disease diagnosis and increased survival with Additionally, several studies have shown a link between improved treatment.
    [Show full text]
  • Alcoholic Liver Disease Postgrad Med J: First Published As 10.1136/Pmj.76.895.280 on 1 May 2000
    280 Postgrad Med J 2000;76:280–286 Alcoholic liver disease Postgrad Med J: first published as 10.1136/pmj.76.895.280 on 1 May 2000. Downloaded from Kevin Walsh, Graeme Alexander Abstract Alcohol is a major cause of liver cirrhosis Box 1: Safe limits for alcohol intake in the Western world and accounts for the x Males = 21 units per week (1 unit = majority of cases of liver cirrhosis seen in glass or half pint) district general hospitals in the UK. The x Females = 14 units per week three most widely recognised forms of alcoholic liver disease are alcoholic fatty liver (steatosis), acute alcoholic hepatitis, and alcoholic cirrhosis. The exact patho- genesis of alcoholic liver injury is still not Box 2: Factors increasing susceptibility clear but immune mediated and free to ALD radical hepatic injury are thought to be x Lifetime intake of alcohol important. There is increasing interest in genetic factors predisposing to hepatic x Female sex injury in susceptible individuals. Diagno- x Genetic factors sis is based on accurate history, raised x Drinking without food serum markers such as ã-glutamyl- Binge drinking transferase, mean corpuscular volume, x and IgA and liver histology when x High concentration alcoholic drinks—for obtainable. Abstinence is the most example, spirits important aspect of treatment. Newer x Drinking multiple diVerent alcoholic drugs such as acamprosate and naltrex- beverages one are used to reduce alcohol craving. Vitamin supplements and nutrition are vital while corticosteroids have a role in acute alcoholic hepatitis where there Danish subjects found that ALD was increased is no evidence of gastrointestinal above a threshold of 7–13 drinks per week in haemorrhage or sepsis.
    [Show full text]